Mesoblast Reduces cash outflows for the quarter
- Mesoblast (MSB) reports cash outflows of US$19.8 million (A$28.3 million) for the quarter, a reduction of 38 per cent from the previous corresponding quarter.
- The company says almost half of this expenditure was used for remestemcel-L regulatory and manufacturing activities
- Revenues for the quarter were US$3.5 million (A$5 million), which includes US$2.3 million (A$3.28 million) from TEMCELL royalties on sales for SR-aGvHD in Japan
- The company finished the quarter with US$94.9 million (A$135.5 million) cash on hand, with an additional US$40 million (A$57.1 million) available to be drawn down from existing financing facilities
- MSB shares up 2.75 per cent higher to $1.12
